Breaking

Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program Eli Lilly's Legal Victory Over Noom's GLP-1 Claims BBSW AI Solution Event: Daily Roundup

🇺🇸 Search Americas

Global entity results · articles filtered to FDA

33 intelligence results for “COPD”

6 patents · 11 trials · 12 pipelines · 4 articles

🇺🇸 Americas articles · global entities

Top match · Patent

Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers Transgenion—International Institute for Regenerative Translational Medicine GmbH View profile →

All results

Patents (6)

Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers — Transgenion—International Institute for Regenerative Translational Medicine GmbH
Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers — Transgenion—International Institute for Regenerative Translational Medicine GmbH
Methods for evaluating COPD status — Veracyte, Inc.
Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers — Transgenion—International Institute for Regenerative Translational Medicine GmbH
Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers — Transgenion—International Institute for Regenerative Translational Medicine GmbH
Methods for treating COPD — The Board of Regents of the University of Texas System

Trials (11)

Pipelines (12)

611 — Sunshine Guojian Pharmaceutical (Shanghai) Co., · phase 3
A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO) — AstraZeneca AB · phase 3
Aclidinium bromide/formoterol Fixed-Dose Combination — AstraZeneca · phase 3
BGF MDI 320/14.4/9.6 μg — AstraZeneca · phase 3
BGF MDI HFO 320/14.4/9.6μg — AstraZeneca · phase 3
CHF 5993 100/6/12.5 µg — Chiesi Farmaceutici S.p.A. · phase 3
CHF6001 DPI, CHF6001 DPI, Placebo to match CHF6001 DPI — Chiesi Farmaceutici S.p.A · phase 3
Indacaterol 150 μg — Novartis Pharmaceuticals · phase 3
Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation” — Kamada BioPharma Limited at Fieldfisher LLP · phase 3
Metformina Uxa 850 mg comprimidos recubiertos con película EFG, El producto denominado Placebo Metformina comprimidos recubiertos está constituido por comprimidos recubiertos blancos que contienen celulosa microcristalina Ph Eur, acondicionados en blisters de PVC/PE/PVDC transparente con aluminio anónimo. — The George Institute · phase 3
Moxifloxacin — United Therapeutics Europe Ltd · phase 3
Placebo, Atoris, 40 mg, tabletki powlekane — Bial Portela & Companhia S.A. · phase 3

Articles (4)